K Number
K073341
Device Name
GENEX PUTTY
Manufacturer
Date Cleared
2008-07-09

(224 days)

Product Code
Regulation Number
888.3045
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
Genex® Putty is a bone void filler intended to fill defects not intrinsic to the stability of the spine and pelvis. Genex® Putty provides a bone void filler that resorbs and is replaced with bone during the healing process.
Device Description
Genex® Putty is a calcium salt bone graft substitute and is provided sterile for single patient use. When Genex® Putty is placed in the defect; bone grows in apposition to the implant, filling the pores with new bone during the healing process. Genex® Putty is completely resorbed and replaced with bone during the healing process.
More Information

Not Found

Not Found

No
The summary describes a bone void filler material and its intended use, with no mention of software, algorithms, or any technology related to AI or ML.

Yes
Genex® Putty is a bone void filler that resorbs and is replaced with bone during the healing process, indicating it is used for therapeutic tissue repair.

No

Explanation: The provided text describes Genex® Putty as a "bone void filler" which "resorbs and is replaced with bone during the healing process." Its intended use is to "fill defects," and it acts as a "calcium salt bone graft substitute." There is no mention of the device detecting, identifying, or monitoring any medical conditions or physiological processes, which are characteristics of a diagnostic device.

No

The device description clearly states that Genex® Putty is a "calcium salt bone graft substitute" and is provided as a physical material ("putty") for filling bone defects. This indicates it is a physical medical device, not software.

No, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In Vitro Diagnostics are medical devices used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
  • Genex® Putty's Function: Genex® Putty is a bone void filler. It is a material implanted directly into the body to fill a physical defect in bone. It does not analyze or test specimens taken from the body.
  • Intended Use: The intended use clearly states it's a "bone void filler intended to fill defects." This is a therapeutic or structural function, not a diagnostic one.

Therefore, based on the provided information, Genex® Putty is a medical device, but it falls under a different category than In Vitro Diagnostics.

N/A

Intended Use / Indications for Use

Genex® Putty is a bone void filler intended to fill defects not intrinsic to the stability of the spine and pelvis.

Genex® Putty provides a bone void filler that resorbs and is replaced with bone during the healing process.

Product codes

MQV

Device Description

Genex® Putty is a calcium salt bone graft substitute and is provided sterile for single patient use. When Genex® Putty is placed in the defect; bone grows in apposition to the implant, filling the pores with new bone during the healing process.

Genex® Putty is completely resorbed and replaced with bone during the healing process.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

spine and pelvis

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Non Clinical Testing
Data supplied demonstrates that Genex® Putty is substantially equivalent to the predicate device and any differences do not raise any concerns regarding safety and effectiveness.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

Not Found

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 888.3045 Resorbable calcium salt bone void filler device.

(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.

0

KO73341

510(k) SUMMARY

JUL - 9 2008

Genex® Putty

Applicant

Biocomposites Ltd Keele Science Park Keele Staffordshire England ST5 SNL

Contact Person

Mr Simon Fitzer Tel: +44 (0) 1782 338580 +44 (0) 1782 338599 Fax Email: sf@biocomposites.com

Classification Name: Common/Usual Name: Trade/Proprietary Name Product Code

Filler, bone void, calcium compound Bone void filler Genex® Putty MQV

Device Description

Genex® Putty is a calcium salt bone graft substitute and is provided sterile for single patient use. When Genex® Putty is placed in the defect; bone grows in apposition to the implant, filling the pores with new bone during the healing process.

Genex® Putty is completely resorbed and replaced with bone during the healing process.

1

K073341 (pg. 1 of 2)

Intended Use / Indications

Genex® Putty is a bone void filler intended to fill defects not intrinsic to the stability of the spine and pelvis.

Genex® Putty provides a bone void filler that resorbs and is replaced with bone during the healing process.

Summary of Technology

Genex® Putty has the same technological characteristics as the predicate device and any differences do not raise any concerns regarding safety and effectiveness.

Genex® Putty provides a bone graft substitute that resorbs and is replaced with bone during the healing process.

The indications, contraindications, risks and potential adverse events are the same as the identified predicate device and are thus substantially equivalent.

Non Clinical Testing

Data supplied demonstrates that Genex® Putty is substantially equivalent to the predicate device and any differences do not raise any concerns regarding safety and effectiveness.

Substantial Equivalence

Documentation provided demonstrates that the Genex® Putty is substantially equivalent to the legally marketed predicate device in basic features and intended uses. No new concerns have been identified regarding safety and effectiveness of the new device.

2

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol resembling an eagle or bird in flight, with three curved lines forming the body and wings.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Biocomposites Ltd. % Mr. Simon Fitzer Keele Sciences Park Keele, Staffordshire United Kingdom ST5 5NL

JUL - 9 2008

Re: K073341

Trade/Device Name: Genex® Putty Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone filler device Regulatory Class: Class II Product Code: MQV Dated: July 3, 2008 Received: July 7, 2008

Dear Mr. Fitzer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

3

Page 2 - Mr. Simon Fitzer

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or the Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark M. Millerson

Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

INDICATIONS FOR USE

510(k) Number (if known):

Genex® Putty Device Name:

Indications For Use:

Genex® Putty is a bone void filler intended to fill defects not intrinsic to the stability of the spine and pelvis.

Genex® Putty provides a bone void filler that resorbs and is replaced with bone during the healing process.

OR

Prescription Use (Part 21 CFR 801 Subpart D)

Over
(Part

No Over-The-Counter use (Part 21 CFR 807 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

Jarlare Buerno

Division of General, Restorative, and Neurological Devices

Page 1 of 1

510(k) Number K67 334/